Stock comparison
Gilead Sciences
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GILD
Gilead Sciences
Market cap
$166.82B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Gilead Sciences GILD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GILD | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 60C | 65C | GMAB |
| Benjamin Graham | 73B | 64C | GILD |
| Philip Fisher | 61C | 48D | GILD |
| Peter Lynch | 55C | 25F | GILD |
| Joel Greenblatt | 47D | 76B | GMAB |
| Charlie Munger | 74C | 68C | GILD |
| Terry Smith | 71B | 71C | Tie |
Side-by-side metrics
| Metric | GILD | GMAB |
|---|---|---|
| Market cap | $166.82B | $16.5B |
| P/E (TTM) | 17.5x | 6.2x |
| EV/EBIT | 15.0x | 12.0x |
| ROIC (TTM) | 20.31% | 43.78% |
| Gross margin | 79.35% | 93.88% |
| Net margin | 30.99% | 18.23% |
| Revenue CAGR 5y | 1.9% | -18.45% |
| EPS CAGR 5y | 8.37% | -23.48% |
| Debt / Equity | 0.9x | 0.1x |
| Dividend yield | 2.46% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GILD leads on
- EPS CAGR 5y8.37%vs -23.48%+136%
- Revenue CAGR 5y1.9%vs -18.45%+110%
- Dividend yield2.46%vs 0.0%+100%
- Market cap$166.82Bvs $16.5B+90%
GMAB leads on
- Debt / Equity0.1xvs 0.9x+92%
- P/E (TTM)6.2xvs 17.5x+65%
- ROIC (TTM)43.78%vs 20.31%+54%
- EV/EBIT12.0xvs 15.0x+20%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.